Management of Gamma-Butyrolactone Dependence with Assisted Self-Administration of GBL
- PMID: 25054071
- PMCID: PMC4099022
- DOI: 10.1155/2014/485178
Management of Gamma-Butyrolactone Dependence with Assisted Self-Administration of GBL
Abstract
Gamma-hydroxybutyric acid (GHB) and its liquid precursor gamma-butyrolactone (GBL) have become increasingly popular beyond the clubbing culture resulting in daily consumption and dependence in the broader population. This case report illustrates the challenges of managing GHB-withdrawal and a possibly superior future approach of its management by titration and tapering of the addictive agent.
References
-
- Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug and Alcohol Dependence. 2001;63(1):1–22. - PubMed
-
- Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clinical Toxicology. 2012;50(6):458–470. - PubMed
-
- McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug and Alcohol Dependence. 2004;75(1):3–9. - PubMed
-
- Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Annals of Emergency Medicine. 2001;37(2):147–153. - PubMed
-
- Bay T, Eghorn LF, Klein AB, Wellendorph P. GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochemical Pharmacology. 2014;87(2):220–228. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources